SequelSEC

Viatris Inc VTRS

Pharmaceutical Preparations · CIK 0001792044 · Fiscal year ends 1231

Revenue
$14.30B
Fiscal year ended 2025-12-31
Operating income
-$2.66B
Fiscal year ended 2025-12-31
Free cash flow
$1.94B
Fiscal year ended 2025-12-31

Viatris Inc (VTRS) reported revenue of $14.30B for the fiscal year ended 2025-12-31. This page shows 8 annual periods of income statement, balance sheet and cash flow figures normalized from Viatris Inc’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Pharmaceutical Preparations.

Income

Viatris Inc income by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312022-12-312021-12-312020-12-312019-12-312018-12-31
Revenue$14.30B$14.74B$15.43B$16.26B$17.89B$11.95B$11.50B$11.43B
Cost of revenue$9.29B$9.12B$8.99B$9.77B$12.31B$8.15B$7.60B$7.43B
Gross profit$5.01B$5.62B$6.44B$6.50B$5.58B$3.80B$3.90B$4.00B
Operating income-$2.66B$10.10M$766.20M$1.61B-$34.00M-$210.80M$715.50M$905.60M
Net incomeUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Research & developmentUnavailableUnavailableUnavailableUnavailable$751.10M$555.10M$639.90M$704.50M
Weighted-average diluted sharesUnavailableUnavailableshares 1.21Bshares 1.22Bshares 1.21Bshares 601.20Mshares 516.50Mshares 516.50M
Pretax income-$3.66B-$623.20M$202.90M$2.81B-$664.40M-$721.20M$154.40M$298.40M
Income tax expense-$150.10M$11.00M$148.20M$734.60M$604.70M-$51.30M$137.60M-$54.10M
Diluted EPS$-3.00$-0.53$0.05$1.71$-1.05$-1.11$0.03$0.68
Selling, general & administrative$3.79B$4.10B$4.07B$4.18B$4.53B$3.34B$2.56B$2.44B
General & administrativeUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Selling & marketingUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Balance

Viatris Inc balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312022-12-312021-12-312020-12-312019-12-312018-12-31
Cash & equivalents$1.32B$734.80M$991.90M$1.26B$701.20M$844.40M$475.60M$388.10M
Total assets$37.19B$41.50B$47.69B$50.02B$54.84B$61.55B$31.26BUnavailable
Current assets$9.79B$9.52B$12.98B$10.64B$10.90B$12.87B$6.76BUnavailable
Total liabilities$22.48B$22.87B$27.22B$28.95B$34.35B$38.60B$19.37BUnavailable
Current liabilities$7.09B$5.78B$7.78B$6.75B$9.88B$10.56B$5.57BUnavailable
Total equity incl. NCI$14.71B$18.64B$20.47B$21.07B$20.49B$22.95B$11.88B$12.17B
Temporary (mezzanine) equityUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Inventory$4.00B$3.85B$3.47B$3.52B$3.98B$5.47B$2.67BUnavailable
Accounts receivable$3.03B$3.22B$3.70B$3.81B$4.27B$4.84B$3.06BUnavailable
Goodwill$6.75B$9.13B$9.87B$10.43B$12.11B$12.35B$9.59B$9.75B
Long-term debt$12.48B$14.04B$16.19B$18.02B$19.72B$22.43B$11.21BUnavailable
Accounts payableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Cash flow

Viatris Inc cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312022-12-312021-12-312020-12-312019-12-312018-12-31
Operating cash flow$2.32B$2.30B$2.90B$3.00B$3.02B$1.23B$1.80B$2.34B
Capital expenditures$378.80M$326.00M$377.00M$406.00M$457.20M$243.00M$213.20M$252.10M
Investing cash flow-$427.70M$1.80B-$864.50M$1.47B-$117.80M-$301.10M-$525.40M-$1.21B
Financing cash flow-$1.29B-$4.33B-$2.30B-$3.88B-$3.01B-$605.70M-$1.17B-$1.09B
Net change in cash$611.90M-$257.50M-$268.90M$556.30M-$143.80M$358.80M$101.80M$19.40M
Stock-based compensation$177.70M$146.10M$180.70M$116.40M$111.20M$79.20M$56.80M-$3.30M
Common dividends paidUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Common share repurchases$500.50M$250.00M$250.00M$0$0$0$0$432.00M
Depreciation & amortization$2.80B$2.89B$2.74B$3.03B$4.51B$2.22B$2.02B$2.11B

Derived

Viatris Inc derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312022-12-312021-12-312020-12-312019-12-312018-12-31
Free cash flow$1.94B$1.98B$2.52B$2.59B$2.56B$988.80M$1.59B$2.09B
Gross margin35.1%38.2%41.7%40.0%31.2%31.8%33.9%35.0%
Operating margin-18.6%0.1%5.0%9.9%-0.2%-1.8%6.2%7.9%
FCF margin13.5%13.4%16.4%15.9%14.3%8.3%13.8%18.3%
SBC / revenue1.2%1.0%1.2%0.7%0.6%0.7%0.5%-0.0%
Current ratio1.38x1.65x1.67x1.58x1.10x1.22x1.21xUnavailable
Revenue YoY growth-3.0%-4.5%-5.1%-9.1%49.7%3.9%0.6%Unavailable
Net marginUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
R&D / revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable5.6%6.2%
CapEx / revenue2.6%2.2%2.4%2.5%2.6%2.0%1.9%2.2%
Long-term debt / equity0.85xUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Effective tax rateUnavailableUnavailable73.0%26.1%UnavailableUnavailable89.1%-18.1%

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open VTRS in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-08-06View SEC filing
10-Q · Filed 2026-05-07View SEC filing
10-K · Filed 2026-02-26View SEC filing
10-Q · Filed 2025-11-06View SEC filing
10-Q · Filed 2025-08-07View SEC filing
10-Q · Filed 2025-05-08View SEC filing

Companies in the same industry

Every accounting identity this site checks — the balance sheet, the gross profit bridge and the cash flow statement — reconciles in every period shown.